All Updates

All Updates

icon
Filter
Partnerships
XtalPi and EDDC sign MOU to advance automated synthesis
AI Drug Discovery
Nov 22, 2023
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Yesterday
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Yesterday
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Yesterday
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Yesterday
Partnerships
Climeworks partners with Terraset to enable philanthropic support for carbon removal
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Funding
8 Rivers secures investment from JX Nippon to commercialize DAC technology
Carbon Capture, Utilization & Storage (CCUS)
Sep 17, 2024
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Sep 17, 2024
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Sep 17, 2024
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Sep 17, 2024
AI Drug Discovery

AI Drug Discovery

Nov 22, 2023

XtalPi and EDDC sign MOU to advance automated synthesis

Partnerships

  • Google-backed AI drug discovery company XtalPi and Singapore's national drug discovery platform Experimental Drug Development Centre (EDDC), have signed a Memorandum of Understanding (MOU) to integrate automated synthesis solutions and large language models in pharmaceutical research. The terms and financial details of the agreement have not been disclosed.

  • The partnership will leverage XtalPi's robotic and AI techniques in EDDC's R&D processes to focus on automated chemical compound synthesis and AI-based drug discovery, aiming to generate high-quality data, increase research efficiency, and accelerate the development of new drugs. The collaboration also aims to explore the application of advanced AI models by integrating automated experiments, cellular phenotypes, and multi-omics data.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.